Kymera Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics utilizing targeted protein degradation to selectively eliminate disease-causing proteins by harnessing the body's natural protein degradation machinery; its proprietary Pegasus platform supports a pipeline focused primarily on immunology and inflammation disorders, with additional programs in oncology. The company offers investigational oral degraders including KT-621, a first-in-class STAT6 degrader in Phase 1 trials for Th2-mediated diseases such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, bullous pemphigoid and chronic spontaneous urticaria; KT-579, an IRF5 degrader in IND-enabling studies for autoimmune conditions including lupus, Sjögren’s syndrome, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis and dermatomyositis; and KT-485 (SAR447971), a second-generation IRAK4 degrader prioritized by partner Sanofi for clinical advancement in immuno-inflammatory diseases like hidradenitis suppurativa, atopic dermatitis, psoriasis, asthma and others. It also advances a CDK2 molecular glue degrader program in collaboration with Gilead Sciences targeting oncology indications such as breast cancer and other solid tumors where CCNE1 amplification drives resistance to CDK4/6 inhibitors. Founded in 2015 and headquartered in Watertown, Massachusetts, Kymera operates globally with partnerships including Sanofi for IRAK4 degraders outside oncology, providing milestone payments up to $975 million, U.S. co-commercialization option and profit-sharing, and royalties elsewhere; and Gilead for the CDK2 program, offering up to $750 million including $85 million upfront and option fees plus tiered royalties. Recent developments encompass the June 2025 Gilead alliance for CDK2, Sanofi's prioritization of KT-485 for clinical studies by year-end 2025 with a related $20 million preclinical milestone to Kymera, expansion of the immunology pipeline with the IRF5 program (KT-579) announced in May 2025 targeting rheumatic and autoimmune diseases, and positive Phase 1 data for KT-621 and prior IRAK4 degrader KT-474.
Company News
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer